Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company that develops immunotherapeutics for infectious diseases using its proprietary arenavirus platform. Its immuno-oncology pipeline includes HB-700, a next-generation multi-KRAS mutant-targeting investigational immunotherapy for KRAS-mutated cancers such as lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for HPV16-positive head and neck cancers, with enrollment completed in a Phase 1/2 trial; and HB-300, which targets self-antigens for prostate cancer. The company is also developing HB-400 for Hepatitis B and HB-500 for HIV, both in Phase I trials. It has a collaboration and license agreement with Gilead Sciences, Inc. for preclinical research on vaccine products for HBV and HIV. Incorporated in 2011, HOOKIPA Pharma is headquartered in New York, New York.